NeoGenomics Strengthens Board Compensation with Major Equity Awards to Director Green

Rhea-AI Filing Summary

NeoGenomics Director Marjorie C. Green received new equity compensation grants on June 19, 2025, consisting of:

• Stock Options: Granted 16,019 options to buy common stock at an exercise price of $6.95 per share. These options will become exercisable on June 1, 2026, and expire on June 19, 2035.
• Restricted Stock Units (RSUs): Awarded 22,964 RSUs that will vest on June 1, 2026. Once vested, these RSUs convert to common stock with no expiration date.

This Form 4 filing represents standard director compensation equity grants. The combined awards suggest continued commitment to aligning director interests with shareholders through long-term equity incentives. All securities are held directly by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Marjorie C

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.95	06/19/2025		A		16,019		06/01/2026	06/19/2035	Common Stock	16,019	$0	16,019	D
Restricted Stock Unit	$0	06/19/2025		A		22,964		06/01/2026	(1)	Common Stock	22,964	$0	22,964	D

Explanation of Responses:

1. Once vested, the shares of common stock are not subject to expiration.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at NeoGenomics (NEO) on June 19, 2025?

Director Marjorie C. Green received two equity awards: 16,019 stock options with an exercise price of $6.95 and 22,964 restricted stock units (RSUs). The stock options are exercisable from June 1, 2026, and expire on June 19, 2035, while the RSUs also vest beginning June 1, 2026.

What is the exercise price of NEO stock options granted to Director Green?

The stock options were granted with an exercise price of $6.95 per share. These options represent the right to buy 16,019 shares of NeoGenomics common stock at this price.

When do Marjorie Green's NEO stock options and RSUs vest?

Both the stock options and restricted stock units (RSUs) become exercisable/vest starting on June 1, 2026. The stock options have an expiration date of June 19, 2035, while the RSUs have no expiration date once vested.

How many restricted stock units (RSUs) were granted to NEO's director?

Director Marjorie C. Green was granted 22,964 restricted stock units (RSUs) of NeoGenomics stock on June 19, 2025. These RSUs convert to common stock once vested and have no expiration date after vesting.